Global Drug Facility
On Monday July 6, Johnson & Johnson announced a price reduction of the anti-tuberculosis drug bedaquiline, for low- and middle-income countries. Thanks to the support of USAID and the Global Fund, this price reduction could be achieved. The price dropped from $400 to $340 for a six-month treatment regimen.
While coronavirus (COVID-19) dominates the news, we need to remember that another respiratory disease kills 1.5 million people per year: tuberculosis (TB). This is an opportunity to unite forces in the fight against TB and coronavirus.
As procurement agent for Stop TB /GDF, we are glad to share this news update as announced by the Stop TB partnership during the 50th Union Conference for Lung Health in Hyderabad, India.